REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

08/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4568Sa&default-theme=true

RNS Number : 4568S  OptiBiotix Health PLC  08 January 2025

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Directorate change

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that, further to the announcement on 23 October 2024, David Blain
has been appointed to the Board as Finance Director and Company Secretary
effective from 7 January 2025.

 

David is a member of the Institute of Chartered Accountants in England &
Wales and has extensive financial, commercial and Board experience in a number
of private and public companies, including Iksuda Therapeutics Ltd, Applied
Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly
Renovo Group plc). Mr Blain is currently Financial Director (non-board
position) at Iksuda Therapeutics Ltd.

 

David's appointment to this part-time role will see him work closely with the
OptiBiotix team to support the focus on driving each business unit and the
Group to profitability.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of David Jonathan Blain (aged
63):

 

 Current Directorships     Previous Directorships held in the past five years
 Blain Associates Limited  Applied Graphene Materials Limited (formerly Applied Graphene Materials plc)
                           Applied Graphene Materials LLC
                           Applied Graphene Ventures Limited
                           Universal Matter GBR Ltd (formerly Applied Graphene Materials UK Limited)

 

David Blain does not hold any ordinary shares, options or warrants over new
ordinary shares in the Company.

 

There is no further information regarding David Blain required to be disclosed
under the AIM Rules.

 

Stephen O'Hara, CEO of OptiBiotix commented: "We are pleased to confirm the
appointment of David as Finance Director and Company Secretary. The
appointment reflects the Board's focus on managing costs and building revenues
to create profitable business units and an international business with
well-known global brands."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Joint Broker)         Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZDLFBEFLEBBK